134 related articles for article (PubMed ID: 27586408)
1. PLGA nano/micro particles encapsulated with pertussis toxoid (PTd) enhances Th1/Th17 immune response in a murine model.
Li P; Asokanathan C; Liu F; Khaing KK; Kmiec D; Wei X; Song B; Xing D; Kong D
Int J Pharm; 2016 Nov; 513(1-2):183-190. PubMed ID: 27586408
[TBL] [Abstract][Full Text] [Related]
2. Protection against Bordetella pertussis infection following parenteral or oral immunization with antigens entrapped in biodegradable particles: effect of formulation and route of immunization on induction of Th1 and Th2 cells.
Conway MA; Madrigal-Estebas L; McClean S; Brayden DJ; Mills KH
Vaccine; 2001 Feb; 19(15-16):1940-50. PubMed ID: 11228364
[TBL] [Abstract][Full Text] [Related]
3. Immunization with PCEP microparticles containing pertussis toxoid, CpG ODN and a synthetic innate defense regulator peptide induces protective immunity against pertussis.
Garlapati S; Eng NF; Kiros TG; Kindrachuk J; Mutwiri GK; Hancock RE; Halperin SA; Potter AA; Babiuk LA; Gerdts V
Vaccine; 2011 Sep; 29(38):6540-8. PubMed ID: 21771625
[TBL] [Abstract][Full Text] [Related]
4. Adjuvanticity and protective immunity elicited by Bordetella pertussis antigens encapsulated in poly(DL-lactide-co-glycolide) microspheres.
Shahin R; Leef M; Eldridge J; Hudson M; Gilley R
Infect Immun; 1995 Apr; 63(4):1195-200. PubMed ID: 7890372
[TBL] [Abstract][Full Text] [Related]
5. Alternative diphtheria, tetanus and whooping cough immunization schedule to evoke a Th2 tetanus and a Th1 pertussis immune response.
Lavigne MV; Castro M; Andino J; Manghi M
Microbes Infect; 2004 Apr; 6(5):481-4. PubMed ID: 15109963
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the immune response induced by pertussis OMVs-based vaccine.
Bottero D; Gaillard ME; Zurita E; Moreno G; Martinez DS; Bartel E; Bravo S; Carriquiriborde F; Errea A; Castuma C; Rumbo M; Hozbor D
Vaccine; 2016 Jun; 34(28):3303-9. PubMed ID: 27151884
[TBL] [Abstract][Full Text] [Related]
7. Relative contribution of Th1 and Th17 cells in adaptive immunity to Bordetella pertussis: towards the rational design of an improved acellular pertussis vaccine.
Ross PJ; Sutton CE; Higgins S; Allen AC; Walsh K; Misiak A; Lavelle EC; McLoughlin RM; Mills KH
PLoS Pathog; 2013; 9(4):e1003264. PubMed ID: 23592988
[TBL] [Abstract][Full Text] [Related]
8. Effect of different forms of adenylate cyclase toxin of Bordetella pertussis on protection afforded by an acellular pertussis vaccine in a murine model.
Cheung GY; Xing D; Prior S; Corbel MJ; Parton R; Coote JG
Infect Immun; 2006 Dec; 74(12):6797-805. PubMed ID: 16982827
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-12 is produced by macrophages in response to live or killed Bordetella pertussis and enhances the efficacy of an acellular pertussis vaccine by promoting induction of Th1 cells.
Mahon BP; Ryan MS; Griffin F; Mills KH
Infect Immun; 1996 Dec; 64(12):5295-301. PubMed ID: 8945580
[TBL] [Abstract][Full Text] [Related]
10. PLGA (85:15) nanoparticle based delivery of rL7/L12 ribosomal protein in mice protects against Brucella abortus 544 infection: A promising alternate to traditional adjuvants.
Singh D; Somani VK; Aggarwal S; Bhatnagar R
Mol Immunol; 2015 Dec; 68(2 Pt A):272-9. PubMed ID: 26442664
[TBL] [Abstract][Full Text] [Related]
11. Poly-(lactic-co-glycolic-acid)-based particulate vaccines: particle uptake by dendritic cells is a key parameter for immune activation.
Silva AL; Rosalia RA; Varypataki E; Sibuea S; Ossendorp F; Jiskoot W
Vaccine; 2015 Feb; 33(7):847-54. PubMed ID: 25576216
[TBL] [Abstract][Full Text] [Related]
12. Reciprocal protective immunity against Bordetella pertussis and Bordetella parapertussis in a murine model of respiratory infection.
Watanabe M; Nagai M
Infect Immun; 2001 Nov; 69(11):6981-6. PubMed ID: 11598073
[TBL] [Abstract][Full Text] [Related]
13. Induction of a balanced Th1/Th2 immune responses by co-delivery of PLGA/ovalbumin nanospheres and CpG ODNs/PEI-SWCNT nanoparticles as TLR9 agonist in BALB/c mice.
Ebrahimian M; Hashemi M; Maleki M; Abnous K; Hashemitabar G; Ramezani M; Haghparast A
Int J Pharm; 2016 Dec; 515(1-2):708-720. PubMed ID: 27989827
[TBL] [Abstract][Full Text] [Related]
14. Chlamydia trachomatis recombinant MOMP encapsulated in PLGA nanoparticles triggers primarily T helper 1 cellular and antibody immune responses in mice: a desirable candidate nanovaccine.
Fairley SJ; Singh SR; Yilma AN; Waffo AB; Subbarayan P; Dixit S; Taha MA; Cambridge CD; Dennis VA
Int J Nanomedicine; 2013; 8():2085-99. PubMed ID: 23785233
[TBL] [Abstract][Full Text] [Related]
15. Antibody responses in adult and neonatal BALB/c mice to immunization with novel Bordetella pertussis vaccine formulations.
Gracia A; Polewicz M; Halperin SA; Hancock RE; Potter AA; Babiuk LA; Gerdts V
Vaccine; 2011 Feb; 29(8):1595-604. PubMed ID: 21215343
[TBL] [Abstract][Full Text] [Related]
16. Surface-assembled poly(I:C) on PEGylated PLGA microspheres as vaccine adjuvant: APC activation and bystander cell stimulation.
Hafner AM; Corthésy B; Textor M; Merkle HP
Int J Pharm; 2016 Nov; 514(1):176-188. PubMed ID: 27863662
[TBL] [Abstract][Full Text] [Related]
17. Addition of a TLR7 agonist to an acellular pertussis vaccine enhances Th1 and Th17 responses and protective immunity in a mouse model.
Misiak A; Leuzzi R; Allen AC; Galletti B; Baudner BC; D'Oro U; O'Hagan DT; Pizza M; Seubert A; Mills KHG
Vaccine; 2017 Sep; 35(39):5256-5263. PubMed ID: 28823618
[TBL] [Abstract][Full Text] [Related]
18. Bordetella pertussis-specific Th1/Th2 cells generated following respiratory infection or immunization with an acellular vaccine: comparison of the T cell cytokine profiles in infants and mice.
Ryan M; Gothefors L; Storsaeter J; Mills KH
Dev Biol Stand; 1997; 89():297-305. PubMed ID: 9272363
[TBL] [Abstract][Full Text] [Related]
19. Prior Bordetella pertussis infection modulates allergen priming and the severity of airway pathology in a murine model of allergic asthma.
Ennis DP; Cassidy JP; Mahon BP
Clin Exp Allergy; 2004 Sep; 34(9):1488-97. PubMed ID: 15347385
[TBL] [Abstract][Full Text] [Related]
20. Enhancing immunogenicity to PLGA microparticulate systems by incorporation of alginate and RGD-modified alginate.
Mata E; Igartua M; Patarroyo ME; Pedraz JL; Hernández RM
Eur J Pharm Sci; 2011 Sep; 44(1-2):32-40. PubMed ID: 21699977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
